Ben Hirschler on Muck Rack

Ben Hirschler Verified

London
Pharma, Health and Science Correspondent — Reuters

Pharma, health and science writer at Reuters. Any opinions are mine.

Chalkboard newspaper, Monrovia on Twitpic

twitpic.com — Chalkboard newspaper, Monrovia

AbbVie board ditches $55-billion Shire acquisition

theglobeandmail.com — U.S. drug maker AbbVie has pulled the plug on its plan to buy Dublin-based Shire , recommending shareholders vote against the planned $55-billion takeover following new U.S. tax rules. Shire stands to be paid a break-up fee of about $1.64-billion if AbbVie's shareholders follow the advice and reject the transaction.

AbbVie recommends shareholders reject Shire deal

uk.reuters.com — (Reuters) - U.S. pharmaceutical company AbbVie Inc recommended that shareholders vote against its $55 billion takeover of Shire Plc in the wake of a U.S. government move to curb deals designed to cut high taxes.

Geographic split likely for GSK mature drugs sale: sources

reuters.com — Credit: Reuters/Aly Song The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai July 12, 2013. Potential bidders include private equity firm KKR, India's Lupin and Denmark's Lundbeck, all of which are interested in acquiring rights to products in certain regions.

AstraZeneca looks to EU decision for next cancer drug boost

reuters.com — Credit: Reuters/Stefan Wermuth The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. European Medicines Agency experts will consider whether to recommend approval of olaparib at their regular monthly meeting, with a decision expected on Oct. 23 or 24, a company spokeswoman said.

AstraZeneca looks to EU decision for next cancer drug boost

reuters.com — Credit: Reuters/Phil Noble A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. European Medicines Agency experts will consider whether to recommend approval of olaparib at their regular monthly meeting, with a decision expected on Oct. 23 or 24, a company spokeswoman said.

Is this why some drugs don't work, aren't safe? Software 'glitch' mooted

biznews.com — A 'glitch' in one of the most widely used statistical software packages in the pharmaceutical industry, could have compromised the reliability of clinical tests used to approve drugs as safe and effective. These drugs, particularly generics marketed as cheaper and just as effective, will already have been released onto an unsuspecting public in the US, Europe and elsewhere, including South Africa.

Exclusive: Software issue casts doubt over data used to approve some drugs

reuters.com — An official at the London-based European Medicines Agency (EMA) told Reuters that the issue, involving Thermo Fisher Scientific's Kinetica package, would be discussed by European regulators at a meeting next week.

Software issue casts doubt over data used to approve some drugs

dailymail.co.uk — LONDON, Oct 13 (Reuters) - The reliability of clinical tests used to win approval for some medicines -- particularly generic copies of original drugs -- could be in doubt due to an apparent software glitch that may mean data was calculated incorrectly.

UPDATE 1-Smith & Nephew "spray-on-skin" for leg ulcers flops in trial

uk.reuters.com — HP802-247 fails in first of two Phase III trials * Regenerative therapy designed for hard-to-heal ulcers * Shares fall 1.2 percent (Adds analyst comments, shares) By Ben Hirschler LONDON, Oct 13 (Reuters) - A novel spray-on skin treatment consisting of living cells made by Smith & Nephew, which is designed to work with the body's own cells to help heal leg ulcers, has failed in a late-stage clinical trial.
More Articles →
Oct 16, 2014

#Shire drops another 12% today as #AbbVie board ditches planned $55B acquisition reut.rs/1CnXcgx $SHP $ABBV

Oct 13, 2014

RT @DanRebellato: Fancy losing faith in humanity? Why not read Daily Mail readers on Malala winning the Nobel Prize! pic.twitter.com/rntXweVYAT via @SuperRetroid



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Ben Hirschler, email reutersbenhir@muckrack.com.


Share This Profile